References

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

10.3322/caac.21660 · 2021 · External reference

CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020

10.1093/neuonc/noad149 · 2023 · External reference

The 2021 WHO classification of tumors of the central nervous system: a summary

10.1093/neuonc/noab106 · 2021 · External reference

Long-term survival with glioblastoma multiforme

10.1093/brain/awm204 · 2007 · External reference

Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2022

10.1093/noajnl/vdad105 · 2023 · External reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

10.1056/nejmoa043330 · 2005 · External reference

CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021

10.1093/neuonc/noaf168 · 2025 · External reference

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

10.1038/nature07385 · 2008 · External reference

The somatic genomic landscape of glioblastoma

10.1016/j.cell.2013.09.034 · 2013 · External reference

Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study

10.1038/s41698-025-01247-3 · 2026 · External reference

Dabrafenib plus trametinib in patients with BRAF V600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

10.1016/s1470-2045(21)00578-7 · 2022 · External reference

Vorasidenib in IDH1- or IDH2-mutant low-grade glioma

10.1056/nejmoa2304194 · 2023 · External reference

Challenges to curing primary brain tumours

10.1038/s41571-019-0177-5 · 2019 · External reference

Recommendations for robust and reproducible preclinical research in personalised medicine

10.1186/s12916-022-02719-0 · 2023 · External reference

The “ins and outs” of early preclinical models for brain tumor research: are they valuable and have we been doing it wrong

10.3390/cancers11030426 · 2019 · External reference

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

10.1016/s1470-2045(17)30517-x · 2017 · External reference

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial

10.1093/neuonc/noac173 · 2023 · External reference

Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial

10.1001/jamaoncol.2020.1024 · 2020 · External reference

Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages

10.1093/neuonc/noz185 · 2020 · External reference

Phase 0 and window-of-opportunity clinical trial design in neuro-oncology: a RANO review

10.1093/neuonc/noaa149 · 2020 · External reference

18F-labeled brain-penetrant EGFR tyrosine kinase inhibitors for PET imaging of glioblastoma

10.1039/d3sc04424f · 2023 · External reference

Extending our reach: expanding enrollment in brain metastases and primary brain tumor clinical trials

10.1200/edbk_349155 · 2022 · External reference

Supporting friends and family of adults with a primary brain tumour: a systematic review

10.1111/hsc.13586 · 2022 · External reference

Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients

10.1093/neuonc/noaa015 · 2020 · External reference

Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center

10.1016/j.ejca.2019.02.007 · 2019 · External reference

Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply

10.1093/noajnl/vdab008 · 2021 · External reference

Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy

10.1186/s40425-018-0371-5 · 2018 · External reference

Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014

10.1001/jamaoncol.2018.1789 · 2018 · External reference

International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer

10.1200/jco.2013.54.8347 · 2014 · External reference

Treatment of older adult patients with glioblastoma: moving toward the inclusion of a comprehensive geriatric assessment for guiding management

10.3390/curroncol29010032 · 2022 · External reference

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

10.1038/s41591-018-0337-7 · 2019 · External reference

Unresolved reference

External reference

Virtual clinical trials in oncology: overview, challenges, policy considerations, and future directions

10.1200/cci.20.00169 · 2021 · External reference

Unresolved reference

External reference

Pragmatic trials

10.1056/nejmra1510059 · 2016 · External reference

Real-world evidence and real-world data for evaluating drug safety and effectiveness

10.1001/jama.2018.10136 · 2018 · External reference

Design and evaluation of an external control arm using prior clinical trials and real-world data

10.1158/1078-0432.ccr-19-0820 · 2019 · External reference

Leveraging external data in the design and analysis of clinical trials in neuro-oncology

10.1016/s1470-2045(21)00488-5 · 2021 · External reference

Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: results of a phase IIb trial

10.1093/neuonc/noac285 · 2023 · External reference

Novel clinical trial designs in neuro-oncology

10.1007/s13311-022-01284-x · 2022 · External reference

Clinical trial endpoints for patients with gliomas

10.1093/nop/npw034 · 2017 · External reference

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

10.1215/15228517-2007-062 · 2008 · External reference

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

10.1200/jco.2008.19.8721 · 2009 · External reference

Lomustine and bevacizumab in progressive glioblastoma

10.1056/nejmoa1707358 · 2017 · External reference

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

10.1016/s1470-2045(18)30675-2 · 2019 · External reference

GBM AGILE phase II/III Bayesian randomized platform trial: regorafenib evaluation

10.1200/jco-25-01137 · 2026 · External reference

Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection—Update 1

10.1093/neuonc/noae213 · 2025 · External reference

Master protocols to study multiple therapies, multiple diseases, or both

10.1056/nejmra1510062 · 2017 · External reference

Platform trials arrive on time for glioblastoma

10.1093/neuonc/noy040 · 2018 · External reference

Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): a Bayesian adaptive platform trial to develop precision medicines for patients with glioblastoma

10.1200/po.18.00071 · 2019 · External reference

Adaptive global innovative learning environment for glioblastoma: GBM AGILE

10.1188/1078-0432.ccr-17-0764 · 2018 · External reference

Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation: the NCT Neuro Master Match (N2M2) pilot study

10.1093/neuonc/nox216 · 2018 · External reference

Adaptive designs in clinical trials: why use them, and how to run and report them

10.1186/s12916-018-1017-7 · 2018 · External reference

The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design

10.1136/bmj.m115 · 2020 · External reference

A randomized trial of bevacizumab for newly diagnosed glioblastoma

10.1056/nejmoa1308345 · 2014 · External reference

RANO 2.0: update to the Response Assessment in Neuro-Oncology criteria for high- and low-grade gliomas in adults

10.1200/jco.23.01059 · 2023 · External reference

Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group

10.1093/neuonc/noy137 · 2019 · External reference

Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee

10.1093/neuonc/nox087 · 2018 · External reference

Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology working group

10.1016/s1470-2045(22)00222-4 · 2022 · External reference

Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group

10.1093/neuonc/noab020 · 2021 · External reference

Unresolved reference

External reference

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology criteria

10.1093/neuonc/nox029 · 2017 · External reference

Validation of the M.D. Anderson symptom inventory brain tumor module (MDASI-BT)

10.1007/s11060-006-9228-8 · 2006 · External reference

Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825)

10.1093/neuonc/noab011 · 2021 · External reference

Current status and perspectives of interventional clinical trials for glioblastoma: analysis of ClinicalTrials.gov

10.1186/s13014-016-0740-5 · 2017 · External reference

Unresolved reference

External reference